Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity
Proposed mechanism. A Doxorubicin (DOX) targets the BCAA catabolic pathway in TNBCs, by downregulating BCKDK and augmenting clearance of intracellular BCKAs. B Genetic or pharmacological (high BT2 concentration) inhibition of BCKDK results in increased cell death, decreased intracellular BCKAs, dysr...
Main Authors: | Dipsikha Biswas, Logan Slade, Luke Duffley, Neil Mueller, Khoi Thien Dao, Angella Mercer, Shanmugasundaram Pakkiriswami, Yassine El Hiani, Petra C. Kienesberger, Thomas Pulinilkunnil |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-09-01
|
Series: | Cell Death Discovery |
Online Access: | https://doi.org/10.1038/s41420-021-00602-0 |
Similar Items
-
Supplementation of cyanidin-3-O-β-glucoside-rich haskap (Lonicera caerulea L.) berry extract attenuates hepatic lipid dysregulation in diet-induced obese mice
by: Dipsikha Biswas, et al.
Published: (2023-09-01) -
Dataset reporting BCKDK interference in a BCAA-catabolism restricted environment
by: I. Bravo-Alonso, et al.
Published: (2016-06-01) -
Editorial: Novel Concepts in Cardiac Energy Metabolism: From Biology to Disease
by: Thomas Pulinilkunnil, et al.
Published: (2019-07-01) -
Identification of putative allosteric inhibitors of BCKDK via virtual screening and biological evaluation
by: Chunqiong Li, et al.
Published: (2024-12-01) -
Novel Loss of Function Variant in BCKDK Causes a Treatable Developmental and Epileptic Encephalopathy
by: François Boemer, et al.
Published: (2022-02-01)